A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2019
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 17 Dec 2018 Planned End Date changed from 6 Dec 2024 to 24 Oct 2024.
- 17 Dec 2018 Planned initiation date changed from 20 Dec 2018 to 22 Feb 2019.
- 22 Sep 2018 New trial record